Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1930-1932, 2003; 10.1373/clinchem.2003.019398
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schoen, P.
Right arrow Articles by van Oeveren, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schoen, P.
Right arrow Articles by van Oeveren, W.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2003;49:1930-1932.)
© 2003 American Association for Clinical Chemistry, Inc.

Technical Briefs

Serum Carnosinase Activity in Plasma and Serum: Validation of a Method and Values in Cardiopulmonary Bypass Surgery

Pieter Schoena,1, Hilco Everts1, Theo de Boer1 and Wim van Oeveren

1 HaemoProbe BV, L.J. Zielstraweg 1, 9713 GX Groningen, The Netherlands

aauthor for correspondence: fax 31-50-3176790, e-mail pieterschoen@haemoprobe.com

The first 300 words of the full text of this article appear below.

Serum carnosinase (EC 3.4.13.20) is synthesized in the brain, where it is secreted into cerebrospinal fluid and then into the systemic circulation. Its deficiency has been associated with neurologic deficits (1)(2), and decreased concentrations have been observed in patients with Parkinson disease or multiple sclerosis and in patients after a cerebrovascular accident (3). It has also been suggested that measurement of serum carnosinase together with neuron-specific enolase, or their ratio, may be useful in the assessment of patients with acute stroke with respect to diagnosis and prediction of clinical outcome (4).

Carnosinase exists in two isoforms (5). Tissue carnosinase is found in the liver, kidney, and spleen, and serum carnosinase is found in serum (plasma), as well as in the brain and spinal fluid (6). These enzymes result from different gene products and differ not only in their distribution but also in their enzymatic properties (7)(8)(9). Specifically, although under appropriate conditions both isoforms catalyze the hydrolysis of the dipeptide carnosine (ß-alanyl-L-histidine), only serum carnosinase is able to hydrolyze homocarnosine ({gamma}-aminobutyryl-L-histidine) (2)(9)(10).

It is believed that carnosine and homocarnosine have the ability to protect neuronal cells against ischemic injury (11) and oxidative stress (12)(13) as well as to increase their resistance toward functional exhaustion and accumulation of senile features (14).

Ischemic-reperfusion injury is a major adverse event that causes morbidity and mortality after cardiac surgery, especially when extracorporeal circuits are used. Cerebral damage has been correlated to this type of injury and leads to a decrease in neurocognitive function (15). Currently, the possible relationships between cerebral damage, neurocognitive function, carnosine and homocarnosine . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.